Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim
Authors:
Open Access
- 1 February 1998
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 100 (2) , 338-347
Abstract
The effects of different doses of filgrastim on yields of CD34+peripheral blood stem cells were evaluated in patients with breast cancer. 55 were randomized to receive filgrastim 10, 20, 30 or 40 μg/kg/d with more CD34+cells/kg/apheresis harvested after the three highest dose levels. 35 additional patients were randomized to receive 10 or 30 μg/kg. The median number of CD34+cells collected after 10 μg/kg (n= 31) was 0.7 × 106/kg/apheresis (range 0.1–4.4) as compared to 1.2 (range 0.1–6.8) after 30 μg/kg (n= 32) (P= 0.04). Among patients randomized to 10v30 μg/kg, more (50%) achieved 5.0 × 106CD34+cells/kg and less aphereses were required to achieve 2.5 × 106CD34+cells/kg after the higher dose (P= 0.04). In multivariate analyses, patients receiving 10 μg/kg (n= 31) had lower yields of CD34+cells (P= 0.026) and had a 3.3‐fold increase in the probability of not achieving 5.0 × 106CD34+cells/kg as compared to patients receiving 20–40 μg/kg (n= 59). Patients who had received radiation had a 2.9‐fold probability of not achieving 2.5 × 106CD34+cells/kg. These data suggest that, in patients with good marrow reserves, doses of filgrastim > 10 μg/kg/d mobilized more CD34+cells and may be useful when high numbers of CD34+cells are desired.Keywords
This publication has 25 references indexed in Scilit:
- Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell contentBone Marrow Transplantation, 1997
- Optimization of Peripheral Blood Stem Cell MobilizationStem Cells, 1996
- Transplantation of allogeneic peripheral blood stem cellsStem Cells, 1995
- High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Breast Cancer1995
- Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantationBritish Journal of Haematology, 1994
- Bcl-2 and Fas, Molecules Which Influence Apoptosis. A Possible Role in Systemic Lupus Erythematosus?Autoimmunity, 1994
- Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapyThe Lancet, 1992
- Peripheral Blood Stem Cell Mobilization by Chemotherapy With and Without Recombinant Human Granulocyte Colony-Stimulating FactorJournal of Hematotherapy, 1992
- Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.Journal of Clinical Investigation, 1988
- Reporting results of cancer treatmentCancer, 1981